Asymmetrex Introduces Therapeutic Stem Cell Dosage Technologies to Biotherapeutics Bioprocessing Companies New

Asymmetrex Introduces Therapeutic Stem Cell Dosage Technologies to Biotherapeutics Bioprocessing Companies

Today, May 20, in the virtual 5th Annual MarketsandMarkets Bioprocessing of Biotherapeutics Conference, the President and CEO of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., introduced company executives and scientists to new technologies for determining the dosage of therapeutic stem cell products and treatments. A Gold Sponsor for the conference, Asymmetrex’s kinetic

Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials

Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials

On September 30, stem cell biotechnology company Asymmetrex presented at the 2020 Outsourcing in Clinical Trials USA Virtual Conference. In addition to discussing the value of tissue stem cell counting for better practices in stem cell and gene therapy clinical trials, Asymmetrex director James Sherley also highlighted value that stem cell counting technologies can impart

New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem Cells

New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem Cells

In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the

Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting

Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting

Today, June 16, Massachusetts stem cell biotechnology company Asymmetrex announces that it will begin offering free tissue stem cell counting on its company website. Scheduled for opening July 5, Independence Day weekend in the U.S., the company’s counting site will give academic scientists, stem cell medicine physicians, tissue stem cell suppliers, and drug companies a

Asymmetrex Director Sherley Addresses the Clinical Trial Supply Industry About the Benefits of Stem Cell Counting

May 12, 2020   In Arena International’s Clinical Trial Supply 2020 Virtual Experience online conference, Asymmetrex Director James Sherley discussed unique challenges in the supply chain of therapies for stem cell transplantation medicine, gene therapy, and gene-editing therapy that can be readily addressed by greater use of tissue stem cell counting technologies like those developed

Asymmetrex Obtains UK Patent for Tissue Stem Cell-Specific Counting and Testing

Asymmetrex Obtains UK Patent for Tissue Stem Cell-Specific Counting and Testing

On October 2, 2019, the United Kingdom Intellectual Property Office issued a patent to Massachusetts stem cell biotechnology company Asymmetrex. The patent covers the company’s invention of the first and only technology for counting tissue stem cells specifically and identifying agents that affect tissue stem cells, positively or negatively. The new patent is another advance

Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells

Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells

On May 16, at the ASTM International May Committee Meeting in Denver, Colorado, Massachusetts stem cell biotechnology company Asymmetrex received unanimous approval of its proposal for an interlaboratory evaluation of the company’s AlphaSTEM Test™ technology for counting therapeutic adult tissue stem cells. Highlighting the importance of the approval, a day earlier, the Standards Coordinating Body